Chinese multidisciplinary expert consensus on combined immunotherapy based on immune checkpoint inhibitors for hepatocellular carcinoma(2021 version).
10.3760/cma.j.cn501113-20210604-00261
- Collective Name:Chinese Chapter of the International Hepato-Pancreato-Biliary Association;;Group of Liver Surgery, Surgical Society of Chinese Medical Association;;Expert Committee on Liver Cancer, Chinese Society of Clinical Oncology
- Publication Type:Journal Article
- Keywords:
Combination therapy;
Consensus;
Hepatocellular carcinoma;
Immune checkpoint inhibitors;
Immunotherapy;
Multi-disciplinary treatment
- MeSH:
Carcinoma, Hepatocellular/drug therapy*;
China;
Consensus;
Humans;
Immune Checkpoint Inhibitors;
Immunotherapy;
Liver Neoplasms/drug therapy*
- From:
Chinese Journal of Hepatology
2021;29(7):636-647
- CountryChina
- Language:Chinese
-
Abstract:
Combined immunotherapy based on immune checkpoint inhibitors (ICIs) for hepatocellular carcinoma has achieved remarkable therapeutic effect in clinical research and practice. However, many problems that need to be resolved have also been recognized in the clinical promotion process. Therefore, the primary effort through the multidisciplinary experts' mutual discussion [Chinese multidisciplinary expert consensus on combined immunotherapy based on immune check point inhibitors for hepatocellular carcinoma (2021 version)] is to implement the principles and methods of clinical application of ICIs treatment, including the selection of indications, prescriptions, treatment methods, monitoring and management of treatment process and adverse reactions, and efficacy evaluation. In addition, the consensus aims to combine the latest research progress, summarize detailed clinical application rules and expert experience, so as to provide reference for health professionals.
